AR053331A1 - Terapia combinada - Google Patents
Terapia combinadaInfo
- Publication number
- AR053331A1 AR053331A1 ARP060100465A ARP060100465A AR053331A1 AR 053331 A1 AR053331 A1 AR 053331A1 AR P060100465 A ARP060100465 A AR P060100465A AR P060100465 A ARP060100465 A AR P060100465A AR 053331 A1 AR053331 A1 AR 053331A1
- Authority
- AR
- Argentina
- Prior art keywords
- therapy
- effective amount
- pharmaceutical composition
- weight gain
- adverse weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- AIDS & HIV (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
Abstract
Uso de inhibidores de SDC-1 de la formula (1) donde x, y, V, W, G, J, L, M, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 y R8a tienen los valores que se definen, en combinacion con otras terapias medicinales para tratar el aumento de peso adverso Reivindicacion 1: Un método para tratar el aumento de peso adverso asociada con una terapia con medicamentos caracterizado porque comprende administrar a un sujeto que lo necesita una cantidad eficaz en términos terapéuticos de un inhibidor de SCD-1 en conjuncion con a un diluyente o vehículo aceptable para uso farmacéutico. Reivindicacion 2: El método de la reivindicacion 1, caracterizado porque dicha terapia con medicamentos se selecciona del grupo formado por antidiabéticos, anti- depresivos, anti-psicoticos, anti-convulsivos, anti-epilépticos, anticonceptivos orales, terapias contra el cáncer, terapia preventiva de la migrana, terapia para condiciones inflamatorias sistémicas, terapia contra la endometriosis, terapia contra la osteoporosis, terapia para el crecimiento del cabello y terapia contra el HIV. Reivindicacion 24: Una composicion farmacéutica caracterizada porque comprende una cantidad eficaz en términos terapéuticos de una terapia con drogas que tiene un efecto colateral de aumento de peso adverso, y una cantidad eficaz en términos terapéuticos de un inhibidor de SCD-1. Reivindicacion 28: Una composicion farmacéutica de la reivindicacion 27, en donde dicha terapia antidiabética se selecciona del grupo formado por una sulfonil urea, una meglitinida, un agonista de PPAR-y, e insulina. Reivindicacion 29: Una composicion farmacéutica de la reivindicacion 28 caracterizada porque dicho agonista de PPAR-y es un rosiglitazone o pioglitazone.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65158405P | 2005-02-09 | 2005-02-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR053331A1 true AR053331A1 (es) | 2007-05-02 |
Family
ID=36603292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060100465A AR053331A1 (es) | 2005-02-09 | 2006-02-09 | Terapia combinada |
Country Status (13)
Country | Link |
---|---|
US (1) | US7919484B2 (es) |
EP (1) | EP1846035B1 (es) |
JP (1) | JP2008530097A (es) |
CN (1) | CN101163504A (es) |
AR (1) | AR053331A1 (es) |
AT (1) | ATE525088T1 (es) |
AU (1) | AU2006212761B2 (es) |
BR (1) | BRPI0606143A2 (es) |
CA (1) | CA2597067A1 (es) |
GT (1) | GT200600046A (es) |
MX (1) | MX2007009592A (es) |
TW (1) | TW200638945A (es) |
WO (1) | WO2006086445A2 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE556056T1 (de) * | 2003-07-29 | 2012-05-15 | Xenon Pharmaceuticals Inc | Pyridylderivate und deren verwendung als therapeutische mittel |
US20090118296A1 (en) * | 2005-07-20 | 2009-05-07 | Merck Frosst Canada Ltd. | Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase |
AU2006326815A1 (en) | 2005-12-20 | 2007-06-28 | Merck Frosst Canada Ltd. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
BRPI0717769A2 (pt) | 2006-10-17 | 2013-11-05 | Nuvo Res | Formulação de gel, método para o tratamento da osteoartrite em um indivíduo sofrendo de dor articular, e, uso de diclofenac de sódio |
TW200826936A (en) | 2006-12-01 | 2008-07-01 | Merck Frosst Canada Ltd | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
AR064965A1 (es) * | 2007-01-26 | 2009-05-06 | Merck Frosst Canada Inc | Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa |
US8575167B2 (en) | 2007-02-06 | 2013-11-05 | Takeda Pharmaceutical Company Limited | Spiro compounds having stearoyl-CoA desaturase action |
CA2833209C (en) * | 2007-04-27 | 2016-06-28 | Purdue Pharma L.P. | Piperidine and piperazine compounds as trpv1 antagonists |
CA2687754C (en) | 2007-06-08 | 2015-12-08 | Janssen Pharmaceutica N.V. | Piperidine, piperazine derivatives for use as dgat inhibitors |
AU2008258549B2 (en) | 2007-06-08 | 2013-11-14 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
WO2008148851A1 (en) | 2007-06-08 | 2008-12-11 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
WO2008157844A1 (en) | 2007-06-21 | 2008-12-24 | Forest Laboratories Holdings Limited | Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase |
BRPI0817211A2 (pt) | 2007-09-20 | 2017-05-16 | Irm Llc | composto composições como moduladores da atividade de gpr119 |
WO2009147170A2 (en) | 2008-06-05 | 2009-12-10 | Janssen Pharmaceutica Nv | Drug combinations comprising a dgat inhibitor and a ppar-agonist |
WO2010028761A1 (de) * | 2008-09-09 | 2010-03-18 | Sanofi-Aventis | 2-heteroaryl-pyrrolo[3, 4-c]pyrrol-derivate und ihre verwendung als scd inhibitoren |
EP2350054A4 (en) * | 2008-10-17 | 2012-03-28 | Merck Canada Inc | AZETIDINE DERIVATIVES AS INHIBITORS OF THE STEAROYL COENZYME A DELTA 9 DESATURASE |
US20110293562A1 (en) * | 2009-02-12 | 2011-12-01 | Proyecto De Biomedicina Cima, S.L. | Use of cardiotrophin-1 for the treatment of metabolic diseases |
EP2398809B1 (en) | 2009-02-17 | 2015-07-08 | Merck Canada Inc. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
US8618164B2 (en) | 2009-03-31 | 2013-12-31 | Nuvo Research Inc. | Treatment of pain with topical diclofenac compounds |
US8546450B1 (en) | 2009-03-31 | 2013-10-01 | Nuvo Research Inc. | Treatment of pain with topical diclofenac compounds |
GB0907425D0 (en) * | 2009-04-29 | 2009-06-10 | Glaxo Group Ltd | Compounds |
EP2459568A4 (en) | 2009-07-28 | 2013-02-27 | Merck Frosst Canada Ltd | NOVEL SPIRO COMPOUNDS USEFUL AS DELTA-9 DEATURASE STEAROYL COENZYME INHIBITORS |
US20110101885A1 (en) * | 2009-11-02 | 2011-05-05 | Eric Yang | Led backlight circuit for lcd panels |
KR101701943B1 (ko) | 2009-11-13 | 2017-02-02 | 도레이 카부시키가이샤 | 당뇨병의 치료 또는 예방약 |
WO2012173952A1 (en) * | 2011-06-13 | 2012-12-20 | Emory University | Piperazine derivatives, compositions, and uses related thereto |
UA113288C2 (xx) | 2011-06-22 | 2017-01-10 | Trpv1 антагоністи, що містять дигідроксизамісник, і їх застосування | |
RU2014149559A (ru) | 2012-05-22 | 2016-06-27 | Ийсум Рисёч Девелопмент Кампани Оф Зэ Хибру Юниверсити Оф Иерусалим Лтд. | Селективные ингибиторы недифференцированных клеток |
US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
AU2018205275B2 (en) | 2017-01-06 | 2024-05-02 | Janssen Pharmaceutica Nv | Methods for the treatment of neurological disorders |
CN109311897B (zh) | 2017-03-20 | 2021-07-20 | 福马治疗股份有限公司 | 作为丙酮酸激酶(pkr)活化剂的吡咯并吡咯组合物 |
WO2019084157A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES THEREOF |
US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
US20230055923A1 (en) | 2018-09-19 | 2023-02-23 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9614238D0 (en) * | 1996-07-06 | 1996-09-04 | Zeneca Ltd | Chemical compounds |
EP1100511A2 (en) * | 1998-06-08 | 2001-05-23 | Sambasiva R. Chavali | Inhibition of delta-9-desaturase activity by saponins |
US20030064950A1 (en) * | 2001-02-23 | 2003-04-03 | Ntambi James M. | Methods for reducing body fat and increasing lean body mass by reducing stearoyl-CoA desaturase 1 activity |
EP1388352A1 (en) | 2002-08-08 | 2004-02-11 | Laboratoires Fournier S.A. | Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment |
WO2004047746A2 (en) | 2002-11-21 | 2004-06-10 | Bayer Pharmaceuticals Corporation | Regulation of stearoyl-coa desaturase to treat obesity |
US20040122033A1 (en) * | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
CA2521175A1 (en) * | 2003-04-07 | 2004-10-28 | Kalypsys, Inc. | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
US20070099884A1 (en) | 2003-06-06 | 2007-05-03 | Erondu Ngozi E | Combination therapy for the treatment of diabetes |
NZ545265A (en) * | 2003-07-30 | 2009-11-27 | Xenon Pharmaceuticals Inc | Pyridazine derivatives and their use for treating diseases mediated by stearoyl-CoA desaturase (SCD) enzymes |
EP2289510A1 (en) * | 2004-09-20 | 2011-03-02 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
-
2006
- 2006-02-07 GT GT200600046A patent/GT200600046A/es unknown
- 2006-02-08 AT AT06734555T patent/ATE525088T1/de not_active IP Right Cessation
- 2006-02-08 BR BRPI0606143-5A patent/BRPI0606143A2/pt not_active IP Right Cessation
- 2006-02-08 JP JP2007555181A patent/JP2008530097A/ja active Pending
- 2006-02-08 WO PCT/US2006/004383 patent/WO2006086445A2/en active Application Filing
- 2006-02-08 MX MX2007009592A patent/MX2007009592A/es not_active Application Discontinuation
- 2006-02-08 CA CA002597067A patent/CA2597067A1/en not_active Abandoned
- 2006-02-08 AU AU2006212761A patent/AU2006212761B2/en not_active Ceased
- 2006-02-08 EP EP06734555A patent/EP1846035B1/en not_active Not-in-force
- 2006-02-08 US US11/815,739 patent/US7919484B2/en not_active Expired - Fee Related
- 2006-02-08 CN CNA2006800097246A patent/CN101163504A/zh active Pending
- 2006-02-09 TW TW095104441A patent/TW200638945A/zh unknown
- 2006-02-09 AR ARP060100465A patent/AR053331A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2006086445A3 (en) | 2006-09-14 |
CA2597067A1 (en) | 2006-08-17 |
TW200638945A (en) | 2006-11-16 |
MX2007009592A (es) | 2007-10-16 |
WO2006086445A2 (en) | 2006-08-17 |
JP2008530097A (ja) | 2008-08-07 |
EP1846035A2 (en) | 2007-10-24 |
EP1846035B1 (en) | 2011-09-21 |
BRPI0606143A2 (pt) | 2009-06-02 |
ATE525088T1 (de) | 2011-10-15 |
CN101163504A (zh) | 2008-04-16 |
GT200600046A (es) | 2006-09-25 |
AU2006212761B2 (en) | 2009-07-02 |
AU2006212761A1 (en) | 2006-08-17 |
WO2006086445A8 (en) | 2006-12-07 |
US20090131447A1 (en) | 2009-05-21 |
US7919484B2 (en) | 2011-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR053331A1 (es) | Terapia combinada | |
TW200624427A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
TW200626572A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
TW200626155A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
TW200626592A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
TW200626154A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
MD2447G2 (ro) | Compoziţie farmaceutică, utilizarea ei şi metodă de tratare a cefaleei, migrenei, greţurilor şi vomei | |
DE60011589D1 (de) | Hochwirksame dihydroergotaminhaltige arzneizusammensetzungen | |
UY26724A1 (es) | Métodos y composiciones para tratar el virus de la hepatitis c | |
ECSP066313A (es) | Derivados de la piridazina y su uso como agentes terapéuticos | |
ECSP066315A (es) | Derivados de la piridazina y su uso como agentes terapéuticos | |
AP1780A (en) | Use of cox-2 inhibitors for preventing immunodeficiency. | |
UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
HUP0301405A2 (hu) | Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények | |
TR200201317T2 (tr) | Sinerjistik kombinasyon. | |
AR048324A1 (es) | Metodos para tratar infecciones por vih | |
AR048439A1 (es) | Composiciones farmaceuticas y metodos para tratar la infeccion por vih | |
YU2494A (sh) | Farmaceutska formulacija za tretiranje zavisnosti od nikotina | |
SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
AR030939A1 (es) | Compuesto derivado de pirrolidina sustituida, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento para modular los efectos del receptor de histamina -3 | |
EA200001010A1 (ru) | Применение дексмедетомидина для седативного воздействия в отделении интенсивной терапии | |
ATE361918T1 (de) | 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2- yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden | |
AR002027A1 (es) | Formulaciones transdermicas y proceso para prepararlas. | |
AR026254A1 (es) | El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4 | |
BR0211970A (pt) | Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |